Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie K Jones

Showing results (61-70 of 157) with videos related to

Pageof 16
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 19, 2016
N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodentsAndrew S Felts, Alice L Rodriguez, Ryan D Morrison, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2018
Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5Andrew S Felts, Katrina A Bollinger, Christopher J Brassard, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2022
Discovery of a potent M<sub>5</sub> antagonist with improved clearance profile. Part 1: Piperidine amide-based antagonistsRory A Capstick, David Whomble, Douglas L Orsi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2014
Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profilesJerri M Rook, Mohammed N Tantawy, Mohammad S Ansari, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 17, 2017
OCD candidate gene <i>SLC1A1</i>/EAAT3 impacts basal ganglia-mediated activity and stereotypic behaviorIsaac D Zike, Muhammad O Chohan, Jared M Kopelman, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.
Journal of Medicinal Chemistry|January 21, 2011
Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in ratsDarren W Engers, Julie R Field, Uyen Le, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2008
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsAshley E Brady, Carrie K Jones, Thomas M Bridges, et al.
Neuron|December 22, 2017
Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M<sub>4</sub> Muscarinic ReceptorMark S Moehle, Tristano Pancani, Nellie Byun, et al.
Science Signaling|February 21, 2019
Disabling the Gβγ-SNARE interaction disrupts GPCR-mediated presynaptic inhibition, leading to physiological and behavioral phenotypesZack Zurawski, Analisa D Thompson Gray, Lillian J Brady, et al.
Pageof 16

Showing results (61-70 of 157) with videos related to

Sort By:
Pageof 16
Bioorganic & Medicinal Chemistry Letters|March 19, 2016
N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodentsAndrew S Felts, Alice L Rodriguez, Ryan D Morrison, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2018
Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5Andrew S Felts, Katrina A Bollinger, Christopher J Brassard, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2022
Discovery of a potent M<sub>5</sub> antagonist with improved clearance profile. Part 1: Piperidine amide-based antagonistsRory A Capstick, David Whomble, Douglas L Orsi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2014
Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profilesJerri M Rook, Mohammed N Tantawy, Mohammad S Ansari, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 17, 2017
OCD candidate gene <i>SLC1A1</i>/EAAT3 impacts basal ganglia-mediated activity and stereotypic behaviorIsaac D Zike, Muhammad O Chohan, Jared M Kopelman, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.
Journal of Medicinal Chemistry|January 21, 2011
Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in ratsDarren W Engers, Julie R Field, Uyen Le, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2008
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsAshley E Brady, Carrie K Jones, Thomas M Bridges, et al.
Neuron|December 22, 2017
Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M<sub>4</sub> Muscarinic ReceptorMark S Moehle, Tristano Pancani, Nellie Byun, et al.
Science Signaling|February 21, 2019
Disabling the Gβγ-SNARE interaction disrupts GPCR-mediated presynaptic inhibition, leading to physiological and behavioral phenotypesZack Zurawski, Analisa D Thompson Gray, Lillian J Brady, et al.
Pageof 16